847 related articles for article (PubMed ID: 30972933)
21.
Corfield J; Perera M; Bolton D; Lawrentschuk N
World J Urol; 2018 Apr; 36(4):519-527. PubMed ID: 29344682
[TBL] [Abstract][Full Text] [Related]
22. Prostate penile metastasis: Incidence and imaging pattern on
Tatkovic A; McBean R; Schoeman J; Wong D
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):499-504. PubMed ID: 32449823
[TBL] [Abstract][Full Text] [Related]
23. Frusemide aids diagnostic interpretation of
Fennessy N; Lee J; Shin J; Ho B; Ali SA; Paschkewitz R; Emmett L
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):739-744. PubMed ID: 28623852
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
[TBL] [Abstract][Full Text] [Related]
25. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
[TBL] [Abstract][Full Text] [Related]
26. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
27. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
28. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Ferraro DA; Burger IA
Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
[TBL] [Abstract][Full Text] [Related]
29.
De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P
Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
[TBL] [Abstract][Full Text] [Related]
30. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.
McEwan LM; Wong D; Yaxley J
J Med Imaging Radiat Oncol; 2017 Aug; 61(4):503-505. PubMed ID: 28349676
[TBL] [Abstract][Full Text] [Related]
31. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
Arafa AT; Jain A; Skrobanek P; Humphrey B; Froelich JW; Antonarakis ES
Prostate; 2023 Jun; 83(9):863-870. PubMed ID: 36999911
[TBL] [Abstract][Full Text] [Related]
32.
Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
[TBL] [Abstract][Full Text] [Related]
33. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
34.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
35. Application of [
Dadgar H; Emami F; Norouzbeigi N; Vafaee MS; Jafari E; Gholamrezanezhad A; Assadi M; Ahmadzadehfar H
Mol Imaging Biol; 2020 Aug; 22(4):1062-1069. PubMed ID: 31758511
[TBL] [Abstract][Full Text] [Related]
36. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
37. Impact of
Sonni I; Eiber M; Fendler WP; Alano RM; Vangala SS; Kishan AU; Nickols N; Rettig MB; Reiter RE; Czernin J; Calais J
J Nucl Med; 2020 Aug; 61(8):1153-1160. PubMed ID: 31924715
[TBL] [Abstract][Full Text] [Related]
38. Comparative study between
Wong HS; Leung J; Bartholomeusz D; Sutherland P; Le H; Nottage M; Iankov I; Chang JH
J Med Imaging Radiat Oncol; 2018 Dec; 62(6):816-822. PubMed ID: 30152050
[TBL] [Abstract][Full Text] [Related]
39. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
[TBL] [Abstract][Full Text] [Related]
40. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
